Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Should l Buy HIMS?
Source: CNBC
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 29.760
Low
16.50
Averages
32.95
High
60.00
Current: 29.760
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Amazon's GLP-1 Program Limits Impact Hims
- Amazon's GLP-1 Program Limits: Citi highlighted that Amazon's $29 telehealth option is restricted to prescription renewals, not new prescriptions, which may reduce the competitive threat to Hims' subscription model, impacting its market position.
- Hims Stock Volatility: Hims & Hers Health, Inc. (HIMS) saw its shares drop over 4% to $29.76 in extended trading on Tuesday, although they rebounded by more than 1% after hours, indicating mixed market sentiment regarding its future prospects.
- Hims Expanding New Areas: Hims is diversifying into hormone health, with the FDA recently encouraging testosterone therapy exploration for men with low libido, potentially opening new market opportunities while also advancing FDA-approved GLP-1 therapies.
- Positive Market Sentiment: Despite competition from Amazon, Hims has been viewed as “extremely bullish” on Stocktwits, with message volumes surging 384% over the past week, reflecting investor confidence in its innovative capabilities.
See More
Hims & Hers Stock Declines Amid Amazon Competition
- Stock Fluctuation: Hims & Hers Health closed at $29.76, down 4.03%, primarily impacted by Amazon's launch of a competing GLP-1 weight-loss program, although it gained 39.33% over the past week.
- Surge in Trading Volume: Trading volume reached 56.7 million shares, about 50% above the three-month average of 37.8 million shares, indicating increased market interest in the stock.
- Intensified Market Competition: Amazon's same-day delivery service poses a threat to Hims & Hers' core business, especially following the resolution of a legal dispute with Novo Nordisk over weight-loss drugs, which has dampened market sentiment.
- Investor Watch: Investors will closely monitor the potential impact of Amazon's new offering on Hims & Hers' revenue and subscriber numbers, particularly as the company is set to announce its Q1 results on May 11.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 99.53 points to 26,689.87, indicating positive market sentiment that may attract more investor interest.
- Active Stocks: Local Bounti Corporation (LOCL) increased by $1.0305 in pre-market trading, with a volume of 35,128,203 shares, indicating a significant uptick in the company's market activity.
- ETF Performance: Direxion Daily TSLA Bull 2X ETF (TSLL) rose by $0.2 to $13.49, representing a 107.86% increase from its 52-week low, showcasing strong investor confidence in Tesla.
- Earnings Forecast: Intel Corporation (INTC) is scheduled to report earnings on April 23, 2026, with a consensus EPS forecast of -$0.11, reflecting a 2% increase over the previous year, indicating cautious optimism about its future performance.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Amazon's GLP-1 Program Limits Impact Hims
- Amazon's GLP-1 Program Limits: Citi highlighted that Amazon's $29 telehealth option is restricted to prescription renewals, not new prescriptions, which may reduce the competitive threat to Hims' subscription model, impacting its market position.
- Hims Stock Volatility: Hims & Hers Health, Inc. (HIMS) saw its shares drop over 4% to $29.76 in extended trading on Tuesday, although they rebounded by more than 1% after hours, indicating mixed market sentiment regarding its future prospects.
- Hims Expanding New Areas: Hims is diversifying into hormone health, with the FDA recently encouraging testosterone therapy exploration for men with low libido, potentially opening new market opportunities while also advancing FDA-approved GLP-1 therapies.
- Positive Market Sentiment: Despite competition from Amazon, Hims has been viewed as “extremely bullish” on Stocktwits, with message volumes surging 384% over the past week, reflecting investor confidence in its innovative capabilities.
See More
Hims & Hers Stock Declines Amid Amazon Competition
- Stock Fluctuation: Hims & Hers Health closed at $29.76, down 4.03%, primarily impacted by Amazon's launch of a competing GLP-1 weight-loss program, although it gained 39.33% over the past week.
- Surge in Trading Volume: Trading volume reached 56.7 million shares, about 50% above the three-month average of 37.8 million shares, indicating increased market interest in the stock.
- Intensified Market Competition: Amazon's same-day delivery service poses a threat to Hims & Hers' core business, especially following the resolution of a legal dispute with Novo Nordisk over weight-loss drugs, which has dampened market sentiment.
- Investor Watch: Investors will closely monitor the potential impact of Amazon's new offering on Hims & Hers' revenue and subscriber numbers, particularly as the company is set to announce its Q1 results on May 11.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 99.53 points to 26,689.87, indicating positive market sentiment that may attract more investor interest.
- Active Stocks: Local Bounti Corporation (LOCL) increased by $1.0305 in pre-market trading, with a volume of 35,128,203 shares, indicating a significant uptick in the company's market activity.
- ETF Performance: Direxion Daily TSLA Bull 2X ETF (TSLL) rose by $0.2 to $13.49, representing a 107.86% increase from its 52-week low, showcasing strong investor confidence in Tesla.
- Earnings Forecast: Intel Corporation (INTC) is scheduled to report earnings on April 23, 2026, with a consensus EPS forecast of -$0.11, reflecting a 2% increase over the previous year, indicating cautious optimism about its future performance.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
